The short version
Only one company currently supplies this market — there is no backup if it stumbles.
Market view
eletriptan hbr · Tablet, Film Coated
2 marketed package NDCs · 1 active manufacturer
Same drug class
Other molecules FDA puts in Serotonin-1b and Serotonin-1d Receptor Agonist, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.
- meloxicam, rizatriptan· 1 maker
- almotriptan· 2 makers
- rizatriptan benzoate odt· 2 makers
- sumatriptan succinate and naproxen sodium· 2 makers
- sumatriptan and naproxen sodium· 3 makers
- almotriptan malate· 4 makers
- naratriptan· 4 makers
- rizatriptan· 6 makers
- frovatriptan succinate· 8 makers
- eletriptan hydrobromide· 14 makers
- zolmitriptan· 30 makers
- sumatriptan· 34 makers
Common questions
- Is Eletriptan hbr in shortage right now?
- No. FDA does not currently list Eletriptan hbr in shortage. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.
- Who makes Eletriptan hbr?
- 1 company has marketed Eletriptan hbr in the last 30 days, according to the FDA NDC Directory. That is a thin market — if one stops making it, supply is at risk quickly. Every manufacturer and package is listed on this page.
All marketed products
Expand a strength to see its dosage forms, then package sizes, then each manufacturer and NDC. Click an NDC for its full detail page.